ClinicalTrials.gg
CompletedNCT01355471Updated Feb 18, 2021Results posted

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A Phase 3 interventional study of CD07805/47 Gel and Placebo in Rosacea, sponsored by Galderma R&D. Completed at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
3rd of 11
293 · median 205
Started
2011
with 2 others
Phase 3
4 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 5th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.

03

Conditions studied

  • Rosacea

Browse trials for

Keywords

  • rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female who is at least 18 years of age or older.
  2. A clinical diagnosis of facial rosacea.
  3. A Clinician Erythema Assessment (CEA) score of greater than or equal to 3 at Screening and at Baseline/Day 1 (prior to the study drug application).
  4. A Patient Self Assessment (PSA) score of greater than or equal to 3 at Screening and at Baseline/Day 1 (prior to the study drug application).

Key Exclusion Criteria:

  1. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
  2. Presence of three (3) or more facial inflammatory lesions of rosacea.
  3. Current treatment with monoamine oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics, or alpha agonists.
  4. Less than 3 months stable dose treatment with tricyclic antidepressants, cardiac glycosides, beta blockers or other antihypertensive agents.
  5. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    CD07805/47 gel

    Drug: CD07805/47 Gel

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugCD07805/47 Gel

    Drug page: Brimonidine

    applied topically once daily

  • DrugPlacebo

    applied topically once daily

06

What researchers measure

Primary outcomes

  1. Composite Success

    Composite Success is defined as 2-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

    Time frame: Day 29

07

Results

Posted Nov 21, 2013

Participant flow

Participant flow — Overall Study
MilestoneCD07805/47 GelPlacebo
Started148145
Completed141142
Not completed73

Outcome measures

PrimaryComposite Success

Composite Success is defined as 2-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

Time frame:
Day 29
Reported as:
Number · participants
Composite Success
participantsCD07805/47 GelPlacebo
Day 29/ Hour 33613
Day 29 / Hour 63613
Day 29 / Hour 92515
Day 29 / Hour 123014
Statistical analysis
  • CD07805/47 Gel vs Placebo · GEE: Logit link function · p = <0.001Generalized Estimation Equation (GEE) methods with Logit link function and marginal expectation model.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD07805/47 Gel—1/148 (0.7%)0/148 (0%)
Placebo—0/145 (0%)0/145 (0%)
Most frequent serious events
Most frequent serious events
EventCD07805/47 GelPlacebo
AppendicitisInfections and infestations1/1480/145

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CD07805/47 GelPlaceboTotal
<=18 years000
Between 18 and 65 years136134270
>=65 years121123
Age, Continuous
Age, Continuous(years)CD07805/47 GelPlaceboTotal
Mean48.5 ± 11.9446.5 ± 12.1047.5 ± 12.04
Sex: Female, Male
Sex: Female, Male(Participants)CD07805/47 GelPlaceboTotal
Female105108213
Male433780
Region of Enrollment
Region of Enrollment(participants)CD07805/47 GelPlaceboTotal
United States140138278
Canada8715
08

Study locations

15 sites
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Baumann Cosmetic and Research Institute
    Miami Beach, Florida 33140, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Dermatology Specialists Research
    Louisville, Kentucky 40202, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Skin Specialty Dermatology
    New York, New York 10155, United States
  • Haber Dermatology & Cosmetic Surgery
    South Euclid, Ohio 44118, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Palmetto Clinical Trial Services, LLC
    Greenville, South Carolina 29607, United States
  • J&S Studies Inc.
    College Station, Texas 77845, United States
  • Premier Clinical Research
    Spokane, Washington 99201, United States
  • Kirk Barber Research Inc.
    Calgary, Alberta T25 3B3, Canada
  • Nexus Clinical Research
    St John's, Newfoundland and Labrador A1A 5E8, Canada
  • Newlab Clinical Research Inc.
    St. John's, Newfoundland and Labrador A1C2H5, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Nov 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 2 years after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2011
First posted
May 18, 2011
Start
May 2011
Primary completionActual
Nov 2011
CompletionActual
Jan 2012
Results delay requested
Jul 23, 2012
Results first posted
Nov 21, 2013
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01355471
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
May 18, 2011
Start date
May 2011
Primary completion
Nov 2011
Completion
Jan 2012
Results posted
Nov 21, 2013
Last update
Feb 18, 2021

Study contacts

Michael Graeber, MD
study chair · Galderma R&D
Kirk Barber, MD
principal investigator · Kirk Barber Research Inc.
Leslie Baumann, MD
principal investigator · Baumann Cosmetic and Research Institute
Fran Cook-Bolden, MD
principal investigator · Skin Specialty Dermatology
Joseph Fowler, MD
principal investigator · Dermatology Specialists PSC
Steven Grekin, DO
principal investigator · Grekin Skin Institute
Wayne Gulliver, MD
principal investigator · Newlab Clinical Research Inc.
Robert Haber, MD
principal investigator · Haber Dermatology & Cosmetic Surgery
Michael Heffernan, MD
principal investigator · Central Dermatology
Terry Jones, MD
principal investigator · J&S Studies Inc.
Ian Landells, MD
principal investigator · Nexus Clinical Research
Mark Ling, MD
principal investigator · MedaPhase, Inc.
Phoebe Rich, MD
principal investigator · Oregon Dermatology and Research Center
Dow Stough, MD
principal investigator · Burke Pharmaceutical Research
William Werschler, MD
principal investigator · Premier Clinical Research
Patricia Westmoreland, MD
principal investigator · Palmetto Clinical Trials Services, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion